Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q2 2025 · 10-Q
Revenue$3.62M$3.62M−8.4% vs Q2 2024 Net Income-$261.00K-$261.00KN/M vs Q2 2024 EPS Diluted$0.00$0.00— vs Q2 2024 Gross Profit$1,844,000−0.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived$287,000N/M Free Cash Flowderived$238,000N/M Margins · derivedGross margin50.9%+3.9 pt vs Q2 2024
Operating margin-3.6%+11.1 pt vs Q2 2024
Net margin-7.2%+7.6 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 13, 2025 · 44 d after period end